MedTrace Logo

12 / 48 wk Pivotal PFT vs PBO in COPD II

NCT00782509 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 644

Last updated 2014-06-27

Study results available
· View outcomes & findings →

Summary

This primary objective of this study is to compare two doses of BI 1744 CL inhalation solution delivered by the Respimat® inhaler once daily to placebo in patients with chronic obstructive pulmonary disease (COPD).

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

Olodaterol (BI 1744)

Comparison of low and high doses on efficacy and safety in COPD patients

DRUG

Olodaterol (BI 1744)

Comparison of low and high doses on efficacy and safety in COPD patients

DRUG

Placebo

Olodaterol (BI 1744) placebo inhaled orally once daily from the Respimat inhaler

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim · Boehringer Ingelheim

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2010-09-30

Countries

  • United States
  • China
  • Germany
  • Taiwan

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00782509 on ClinicalTrials.gov